ReviewTranslational andrology and urology2018
Active surveillance: a review of risk-based, dynamic monitoring.
Review in Translational andrology and urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 11 citations in OpenAlex.
- Impact of genomic testing on urologists' treatment preference in favorable risk prostate cancer: A randomized trial.Cancer medicine · 2023Trial
- Risk of progression following a negative biopsy in prostate cancer active surveillance.Prostate cancer and prostatic diseases · 2023Article
- The value of time-dependent risk predictions in a screening context - a comprehensive simulation analysis validated on German cancer registry data.BMC medical research methodology · 2022Article
- Active surveillance for prostate cancer-will the discoveries of the last 5 years change the future?Translational andrology and urology · 2021Article
- Personalised biopsy schedules based on risk of Gleason upgrading for patients with low-risk prostate cancer on active surveillance.BJU international · 2021Article
- The Movember Prostate Cancer Landscape Analysis: an assessment of unmet research needs.Nature reviews. Urology · 2020Review
- Evidence-based approach to active surveillance of prostate cancer.World journal of urology · 2020Review
- Personalized Decision Making for Biopsies in Prostate Cancer Active Surveillance Programs.Medical decision making : an international journal of the Society for Medical Decision Making · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Active surveillance (AS) is an important treatment modality aiming to reduce the overtreatment of patients with prostate cancer (PCa) who have a low risk of disease reclassification. After enrolling in AS patients are actively monitored using different diagnostic tests (e.g., prostate specific-antigen, digital rectal exams (DREs), medical imaging, and prostate biopsies). Biopsy is the most burdensome test. We aimed to review schedules for monitoring men on AS. We compare fixed versus risk based dynamic monitoring, where biopsies are scheduled during follow-up based on dynamic risk predictions. Several prediction models and scheduling techniques have been published. All proposed risk prediction models need further external validation. We conclude that risk based, dynamic monitoring is a promising new strategy to further reduce overtreatment in PCa patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.